Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives

Frontiers in Physiology

Esther Roselló-Lletí¹  Manuel Portolés¹  Miguel Rivera¹  Diego Rodríguez-Penas²  Alana Aragón-Herrera²  Sandra Feijóo-Bandín³  José R. González-Juanatey³  Francisca Lago³ 

[1] Cardiocirculatory Unit, Health Research Institute of La Fe University HospitalValencia, Spain;Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and University Clinical HospitalSantiago de Compostela, Spain;Centro de Investigación Biomédica en Red de Enfermedades CardiovascularesMadrid, Spain;

关键词: cardiovascular diseases;    relaxin-2;    metabolism;    inflammation;    therapy;    heart;   

DOI  :  10.3389/fphys.2017.00599

来源: DOAJ

【 摘 要 】

Despite the great effort of the medical community during the last decades, cardiovascular diseases remain the leading cause of death worldwide, increasing their prevalence every year mainly due to our new way of life. In the last years, the study of new hormones implicated in the regulation of energy metabolism and inflammation has raised a great interest among the scientific community regarding their implications in the development of cardiometabolic diseases. In this review, we will summarize the main actions of relaxin, a pleiotropic hormone that was previously suggested to improve acute heart failure and that participates in both metabolism and inflammation regulation at cardiovascular level, and will discuss its potential as future therapeutic target to prevent/reduce cardiovascular diseases.

【 授权许可】

Unknown